Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:MNTA

Momenta Pharmaceuticals (MNTA) Stock Price, News & Analysis

Momenta Pharmaceuticals logo

About Momenta Pharmaceuticals Stock (NASDAQ:MNTA)

Key Stats

Today's Range
$52.48
$52.48
50-Day Range
$52.26
$52.49
52-Week Range
$12.21
$52.53
Volume
N/A
Average Volume
1.94 million shs
Market Capitalization
$6.25 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company's biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

Receive MNTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Momenta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MNTA Stock News Headlines

Genoptix, Momenta Shares Headed for Gains
A new way to play the AI boom (act before November 19)
There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as little as $16 and a brokerage account.
Eastman Kodak, Rambus: After-Hours Trading
See More Headlines

MNTA Stock Analysis - Frequently Asked Questions

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) posted its earnings results on Monday, August, 10th. The biotechnology company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.06. The biotechnology company had revenue of $6.61 million for the quarter, compared to the consensus estimate of $5.84 million. Momenta Pharmaceuticals had a negative trailing twelve-month return on equity of 61.44% and a negative net margin of 757.61%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Momenta Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Exelixis (EXEL), Gilead Sciences (GILD), Novavax (NVAX), Bristol-Myers Squibb (BMY) and Shopify (SHOP).

Company Calendar

Last Earnings
8/10/2020
Today
11/05/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MNTA
CUSIP
60877T10
Fax
N/A
Employees
131
Year Founded
N/A

Profitability

Net Income
$-290,050,000.00
Net Margins
-757.61%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$23.87 million
Book Value
$4.59 per share

Miscellaneous

Free Float
N/A
Market Cap
$6.25 billion
Optionable
Optionable
Beta
1.71
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

This page (NASDAQ:MNTA) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners